A summit focused on accelerating to market the next generation of potent, safe and efficacious CAR-TCR therapies for solid tumor indications, whilst ensuring the accessibility and commercial delivery of currently approved life-changing CAR-TCR therapies to patients around the world.
Topics: Cancer prevention and life style factors in oncoimmunology; Combination therapies with immune checkpoint blockers; T cell exhaustion – mechanisms of resistance; Immunotherapies, non-cell-based; Immunotherapies, cell based; New targets and concepts; Tumor antigens; Vaccination strategies; New trends in technology & informatics; TME analysis; Onco- and immunometabolism; Microbiota in oncoimmunology
The ESMO Congress is the appointment in Europe for clinicians, researchers, patient advocates, journalists and the pharmaceutical industry from all over the world to get together, learn about the latest advances in oncology and translate science into better cancer patient care.
Our conference offers an extensive look across the development and discovery procedures in the Immuno-Oncology field. Day one will focus on the discovery process in Immuno-Oncology such as the key therapeutic strategies like CAR-T Cells therapies, and checkpoint inhibitors. The second stream is dedicated to biomarker development in translational research. Day two will concentrate on clinical aspects of Immuno-Oncology, Stream one focusing on screening techniques and animal models in preclinical development while strategies in trial design and challenges will be widely discussed in stream two.
Key speakers include Executive Directors, Chief Executive Officers and Directors from leading pharma companies within the field such as Merck, Pfizer and Novartis. The conference is co-located with our 4th Annual Biomarkers and Precision Medicine USA Congress, which highlights the latest challenges and developments in clinical biomarkers and personalised medicine. The congresses offer scientific and business discussions with over 300 senior industry experts, ensuring valuable networking and interactive sessions.
This inaugural American Society of Clinical Oncology event, co-hosted by the Thai Society of Clinical Oncology, is the world’s first global summit for oncology innovators. Breakthrough will bring together the very latest in oncology practice, scientific discovery, and technological advances to transform the future of cancer care. Submit your abstract before June 18, 2019.
The 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019) scheduled to take place Nov. 6-10, 2019, at the Gaylord National Hotel & Convention Center in National Harbor, Md.
The hallmark of this series is also to encourage the effective exchange of ideas between basic cancer immunologists, non-immunologists, and clinical oncologists in order to develop approaches that translate to outcomes. This year’s program will feature international leaders in the field, who will expand our knowledge of the microbiome; adverse immunological events; imaging and other new technologies; genetics and epigenomics of immuno-oncology; and immunological signaling pathways. These world-renowned oncologists and researchers will offer their insights on novel cell therapies, biomarkers, vaccines and adjuvants, all in the pursuit of understanding tumor evolution and creating better treatments.
Join workshop Course Directors Drs. George D. Demetri, Susan Band Horwitz, and Pasi A. Jänne for an intensive introduction to translational cancer research. This week-long workshop will provide basic scientists with a better understanding of translational research and strategies for adapting their research for maximum clinical impact. Apply by April 30.
The recent development of immunotherapies to treat cancer has transformed the way that clinicians think about managing their patients with many forms of malignancies. The speed at which basic science and clinical trial information continue to emerge in this area, however, creates practice and/or educational gaps for busy clinicians who strive to maintain state-of-the art care for their patients with cancer. This field is one of the most clinically relevant and exciting areas of novel drug development in oncology.
“But how do I use this information to manage my patients with cancer?”
This is the key question, and the one whose answer ultimately means the most for your patients. The 4th Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing Application will answer that question. Topics of particular interest will be optimal timing of checkpoint inhibitors, identification of patients with cell surface expression of a target antigen who would be good candidates for CAR T-cell treatment, using combination immunotherapies in patients with driver mutations (eg, EGFR/ALK), and the use of combination therapies targeting the IDO pathway in patients with advanced melanoma.
Meeting Chairs: Michel C. Nussenzweig, M.D., Ph.D. and Jeffrey V. Ravetch, M.D., Ph.D, Rockefeller University.
Theme: New Dimensions of Therapeutic Antibodies.
Annual Kunkel Memorial Lecturer: Tadatsugu Taniguchi, PhD, University of Tokyo who will be speaking about advances in the treatment of inflammatory diseases and cancer.
ICoMI 2020 Congress is a forceful and up-to-date platform where open-minded discussions will promote networking between researchers, clinicians, students and all persons involved in the development of science and medicine. It will be a great opportunity to let new creative and innovative ideas make new collaborations and highlight the latest technology that will help us to reduce the time to find new medication or combinations of treatment especially in the field of chronic diseases.